| | علاجات فى طور التنفيذ لفيروسات الكبد | |
| El Helalyaالمؤسسة
تاريخ التسجيل : 08/08/2008
| موضوع: علاجات فى طور التنفيذ لفيروسات الكبد السبت 5 يونيو 2010 - 18:31 | |
| ان شاء الله ربنا يشفى كل مريض وانا على الانترنت لقيت الاخبار دى واعتقد انها جديده عن تطوير علاجات للفيروس Results Lausanne, Switzerland - April 28, 2008 - Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions, particularly oncology, presented positive efficacy results of a phase IIa study with Debio 025, a selective cyclophilin (Cyp) inhibitor with a potent in-vitro and in-vivo anti-hepatitis C (HCV) effect. Data indicates that Debio 025 shows an important additive anti-HCV effect when co-administered with pegylated Interferon (Peg-IFN) alpha-2a to treatment- naïve HCV patients. Debiopharm presented these findings at the 43rd Annual Meeting of the European Association for the Study of the Liver, in Milan, Italy. The double-blind, placebo-controlled study investigated different dose regimens of Debio 025 in combination with alpha-2a Peg-IFN 180 mg/week in treatment naïve chronic HCV mono-infected patients. Ninety patients were randomised to receive either of the following treatment regimens during 29 days: Peg-IFN with placebo; Peg-IFN with Debio 025 200 mg/day; Peg-IFN with Debio 025 600 mg/day; Peg-IFN with Debio 025 1000 mg/day; and Debio 025 1000 mg/day. In patients with genotypes 1 and 4, at day 29, the HCV-RNA reduction was -4.6 log10 IU/mL in the Peg-IFN with Debio 025 600 mg/day arm, and -4.8 log10 IU/mL in the Debio 025 1000 mg/day arm. This was significantly different (p< 0.05) from the Peg-IFN with placebo, as well as the Debio 025 1000 mg/day monotherapy arms, in which the reduction in viral load was respectively -2.49 and -2.20. In these two arms, at day 29, the proportion of subjects with undetectable viral load was 25%. This number increased to 66% in the Peg-IFN with Debio 025 1000 mg/day group. "To obtain these exciting results after an administration period of only one month is promising and demonstrates that Debio 025 will be a breakthrough in the treatment of HCV infections," said Kamel Besseghir, CEO of Debiopharm S.A. "This unique mechanism of action is the first alternative treatment to classic HCV therapies." Debio 025 Debio 025 is a synthetic first-in-class Cyp inhibitor, being tested in humans as a potential anti-HCV drug. Debio 025 binds strongly to Cyp, host cell proteins thought to confer a replication advantage to HCV. Its potent inhibitory activity on the HCV replication was shown in preclinical studies. Previous results of a phase Ib study demonstrate that Debio 025 monotherapy for 15 days induced a strong anti-HCV effect (3.6 log10 reduction) in HIV-1/HCV co-infected patients. (Hepatology, Vol. 47, No 3, 2008, Flisiak et al. "The Cyclophilin Inhibitor Debio-025 Shows Potent Anti-Hepatitis C Effect in Patients Coinfected with Hepatitis C and Human Immunodeficiency Virus). About HCV HCV is the most prevalent liver disease in the world and is considered by the World Health Organization as an epidemic. Because HCV can infect a patient for decades before being discovered, it is often called the "silent" epidemic. Studies suggest that over 200 million people worldwide are infected with HCV, an overall incidence of around 3.3% of the world's population. In the US alone, nearly 4 million people are or have been infected with HCV and of these, 2.7 million have an ongoing chronic infection, the majority being between 40 to 60 years old. A fourfold increase in the number of adults diagnosed with chronic HCV infection is projected from 1990 to 2015, since most persons with chronic HCV infection have yet to be diagnosed but are likely to come to medical attention in the next decade. About Debiopharm Group Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs. Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.65 billion in 2007. For more information on Debiopharm Group, please visit: www.debiopharm.com الكبدى C منقوول الموضوع : علاجات فى طور التنفيذ لفيروسات الكبد المصدر :منتديات تقى الإسلامية الكاتب: El Helalya |
| | | El Helalyaالمؤسسة
تاريخ التسجيل : 08/08/2008
| موضوع: رد: علاجات فى طور التنفيذ لفيروسات الكبد السبت 5 يونيو 2010 - 18:32 | |
| Romark Laboratories Initiates Phase II Study Of Nitazoxanide In Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
Main Category: Liver Disease / Hepatitis Also Included In: Clinical Trials / Drug Trials; Pharma Industry / Biotech Industry Article Date: 19 Apr 2008 - 0:00 PDT
email to a friend printer friendly view / write opinions rate article Current Article Ratings:
Patient / Public: 4 (1 votes) Health Professional: Article Opinions: 0 posts Romark Laboratories, a privately held biopharmaceutical company, announced that it has begun enrolling patients in a U.S. clinical trial to evaluate nitazoxanide for the treatment of chronic hepatitis C. Preliminary data from the study is expected in the second half of 2008.
The study, STEALTH C-3 (Studies to Evaluate Alinia for Treatment of Hepatitis C), is a Phase II randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety and efficacy of nitazoxanide in combination with peginterferon alpha-2a (Pegasys(R), Roche) and ribavirin (Copegus(R), Roche) in treatment naive patients with chronic hepatitis C infected with genotype 1.
The primary objective of STEALTH C-3 is to evaluate sustained virologic response (SVR) with a treatment regimen of 4 weeks of nitazoxanide lead-in therapy followed by 48 weeks of standard of care plus nitazoxanide versus 4 weeks of placebo lead-in followed by 48 weeks of standard of care and placebo. The trial will enroll 60 patients at 15 centers in the U.S.
"Earlier clinical studies in patients with chronic hepatitis C infected with genotype 4 have shown that nitazoxanide improves virologic response rates when used in combination with standard of care," said Dr. Emmet B. Keeffe, Chief Medical Officer of Romark. "This study and our ongoing STEALTH C-2 trial, are designed to evaluate the effect of treatment with nitazoxanide plus standard of care in patients with genotype 1. Future clinical trials will explore new combinations and treatment durations, including current and emerging HCV therapies."
STEALTH C Clinical Development Program
STEALTH C-3 is the latest in a series of clinical trials aimed at gaining a broad understanding of how nitazoxanide may benefit patients with chronic hepatitis C genotype 1 when used in combination with peginterferon and ribavirin. Other studies in the STEALTH C program include the following:
-- STEALTH C-2, a randomized, double-blind, placebo-controlled trial currently enrolling up to 60 patients in the U.S. with chronic hepatitis C genotype 1 who have previously failed to respond to the standard of care with peginterferon and ribavirin. This trial is designed to evaluate the effectiveness and safety of nitazoxanide administered 500 mg twice daily for 4 weeks followed by nitazoxanide plus standard of care for 48 weeks compared to placebo for 4 weeks followed by standard of care plus placebo for 48 weeks.
-- STEALTH C-1, an international study in 120 treatment-naive and interferon-experienced patients with chronic hepatitis C genotype 4. Interim results from the randomized controlled Phase II clinical trial were presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA and demonstrated that 79 percent of interferon-naive patients with chronic hepatitis C genotype 4 receiving nitazoxanide plus the standard of care had a sustained viral response (SVR) at 12 weeks following treatment, compared to 43 percent of patients receiving the standard of care without nitazoxanide. The patients treated with nitazoxanide also experienced no relapse and no more side effects than patients who received the standard of care. Final study results (SVR-24) will be presented at the European Association for the Study of the Liver (EASL) in April 2008.
To learn more about Romark clinical trials currently under way, or to find out if a study is recruiting patients in your area, please visit http://www.romarktrials.com, or http://www.clinicaltrials.gov (for the latter, enter the search terms "nitazoxanide hepatitis United States.")
About Hepatitis C
Hepatitis C is a blood-borne infectious disease that is caused by the hepatitis C virus (HCV). It is the most common cause of chronic hepatitis in the U.S. and may eventually lead to cirrhosis, liver cancer and liver failure. The disease is transmitted by contact with HCV-infected blood. A large majority of those infected do not show symptoms, but fatigue, abdominal pain and nausea can be common. The current standard treatment of care, peginterferon and ribavirin, is effective in about half of all patients treated. According to the Centers for Disease Control, HCV affects an estimated 4.1 million Americans.
About Romark Laboratories
Romark Laboratories (http://www.romark.com), a privately held biopharmaceutical company, has discovered and developed a new class of small molecule antivirals known as thiazolides. The Company is developing nitazoxanide, the first of the thiazolide class, for the treatment of chronic hepatitis C, and is developing other new thiazolides for treating viral diseases including chronic hepatitis B. Alinia(R) (nitazoxanide) is approved by the U.S. Food and Drug Administration and marketed by Romark for the treatment of infections caused by Cryptosporidium or Giardia.
Romark Laboratories http://www.romark.com الموضوع : علاجات فى طور التنفيذ لفيروسات الكبد المصدر :منتديات تقى الإسلامية الكاتب: El Helalya |
| | | El Helalyaالمؤسسة
تاريخ التسجيل : 08/08/2008
| موضوع: رد: علاجات فى طور التنفيذ لفيروسات الكبد السبت 5 يونيو 2010 - 18:34 | |
| Health News Health Videos Forum Advertise Contact News Archive [link] Web Wikipedia Medical Dictionary [link] Liver Disease / Hepatitis News Useful Links Video Library
Liver Disease / Hepatitis News
The latest Liver Disease News & Hepatitis News articles published daily. Includes news on Inflammation of the liver, cirrhosis, cysts, hepatitis A, B and C and much more. Add this Liver Disease rss news feed to your rss reader: Latest News
Nexavar Significantly Extends Overall Survival In Liver Cancer By 47 Percent 19 May 2008 Bayer HealthCare and Onyx Pharmaceuticals, Inc. announced that Nexavar (sorafenib) tablets significantly improved overall survival by 47.3 percent (HR=0.68; p-value=0.014) in patients in the Asia-Pacific region with... [read article] Latest Research On GI Health Presented At DDW 2008 18 May 2008 Colonoscopy: New developments in polyp detection, colonoscopy preparation and sedation techniques that will increase the effectiveness of colonoscopy and ease patient concerns about the procedure will be presented... [read article] From A Set Of Formulas To Visible Changes In Liver Cancer 18 May 2008 With systems biology methods, CancerSys investigates molecular and cell biological processes in the formation of tumors in the liver Systems Biology is a young field with the overall aim of creating a holistic picture of... [read article] Liver Disease / Hepatitis News Articles Archive - Page 1
17 May 2008
Nexavar Significantly Improves Overall Survival By 47 Percent In Asia Pacific Liver Cancer Study 16 May 2008
Schering-Plough Highlights PEGINTRON(TM) And Boceprevir Hepatitis C Data Presentations At Digestive Disease Week (DDW) Annual Meeting Phase II Study Of IMC-A12 For Advanced Liver Cancer Opens For Patient Enrollment New Treatment For Hepatitis C: New Application For Drug Already Approved For Lowering Cholesterol Researchers Close In On Possible Cause Of Autoimmune Liver Disease 15 May 2008
Pharmasset Commences Dosing R7128 Cohorts 3 And 4 For The Treatment Of Chronic Hepatitis C 14 May 2008
Arbios Receives Approval From The FDA To Initiate Pivotal Trial For SEPET(TM) Liver Assist Device 07 May 2008
Liver Disease - Can-Fite Successfully Completed Phase I Clinical Trial With Its 2nd Drug CF102 06 May 2008
EPA Registered Disinfectant Kills Both Known Types Of MRSA 05 May 2008
Health Department Encourages Public To Learn Risk Factors For Viral Hepatitis 03 May 2008
New Findings: The Anti-Fibrotic Mechanism Of Plant Extract Cpd 861 02 May 2008
P-HOP Event To Provide Free Hepatitis C Testing To The Community - P-HOP Recognizes May As Hepatitis Awareness Month 01 May 2008
Managing Chinese Obese Children With Non-Alcoholic Fatty Liver Disease Anti-HAV Antibodies In Beta-Thalassemia High Circulating D-Dimers Are Associated With Presence Of Ascites Anti-HBe May Play A Role In The Progression Of The Disease Of Hepatitis B 29 April 2008
Clinical Update - Debio 025 In Hepatitis C 28 April 2008
European Commission Approves Viread For Chronic Hepatitis B 27 April 2008
Team Develops Safe, Effective RNA Interference Technique - Method Holds Promise For Treating Cancer And Infection Roche's Investigational Hepatitis C Polymerase Inhibitor, R1626, Demonstrated Significant End-of-Treatment Response In Phase IIa Study Final Results Of Ideal Study Presented At Annual Meeting Of The European Association For The Study Of The Liver (EASL) Three Studies Presented At 43rd EASL Showed Higher SVR For PEGASYS(R) (Peginterferon Alfa-2a) Plus Ribavirin Than Peginterferon Alfa-2b Plus Ribavirin BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared To Adefovir At 96 Weeks In Hepatitis B Positive Patients Interim Results From Boceprevir Phase II Study In Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 26 April 2008
Important Progress Toward Control Of Hepatitis B And C 25 April 2008
Biolex Therapeutics Researchers Present Locteron(R) Phase 2a Hepatitis C Trial Results At EASL Conference Gilead Announces 72-Week Data From Two Pivotal Phase III StudiesEvaluating Viread(R) For The Treatment Of Chronic Hepatitis B Data On Investigational Compounds Being Co-Developed By Tibotec For The Treatment Of Chronic Hepatitis C Presented At EASL 2008 Positive Findings In Treating Patients With Advanced Hepatitis C Valeant Pharmaceuticals Highlights Taribavirin Phase IIb Data Presentation At European Association For The Study Of Liver (EASL) Annual Meeting Gilead Announces 72-Week Data From Two Pivotal Phase III Studies Evaluating Viread(R) For The Treatment Of Chronic Hepatitis B Antipodean Pharmaceuticals Announces Results Of Phase 2 Study Of Lead Compound MitoQ(R) NAFLD AND NASH Linked To Metabolic Syndrome And Cardiovascular Disease Pharmasset Adds Two Cohorts To R7128 Hepatitis C Study 24 April 2008
Positive Preclinical Data On HCV Programs At The Annual Meeting Of The European Association For The Study Of The Liver (EASL), Idenix Pharmaceuticals Idenix Pharmaceuticals Presents Positive Preclinical Data On HCV Programs At The Annual Meeting Of The European Association For The Liver Romark Announces Presentation Of New Data For Nitazoxanide In Chronic Hepatitis C At EASL 2008 23 April 2008
In The Battle Against Hospital Infections 'Crime Scene Investigation' Methods Could Help 21 April 2008
Technology To Detect Liver Disease Via Blood Test To Be Developed 19 April 2008
Romark Laboratories Initiates Phase II Study Of Nitazoxanide In Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 18 April 2008
Schering-Plough Highlights PEGINTRON(TM) And Boceprevir Data Presentations At European Association For The Study Of The Liver (EASL) Annual Meeting 17 April 2008
A Phase II Study Of The Efficacy And Tolerability Of Lapatinib In Patients With Advanced Hepatocellular Carcinomas 16 April 2008
Survival Rates Doubled By Combining Liver Cancer Treatments, UVA Researchers Find Delayed Umbilical Cord Clamping: Health Risks And Benefits 14 April 2008
New Technique In Treating Patients With Liver Cancer Proves Effective Researchers Find That Targeted Therapy Combination Overcomes Treatment Resistance In Liver Cancer 11 April 2008
Antipodean Pharmaceuticals Announces Completion Of Phase 2 Study Of Lead Compound MitoQ(R) Researchers Identify Treatment Target For Liver Cancer Recurrence And Survival 09 April 2008
Hepatitis B Virus Triggers Cell 'Suicide' In Patients With Chronic Infection Roche Diagnostics Expands Availability Of Hepatitis C Virus (HCV) Immunoassay 08 April 2008
For Patients With Advanced Liver Cancer, Hope Found In Combination Therapy 03 April 2008
Early-Onset Obesity In Father Linked To Increased Potential For Liver Disease In Child Delcath Systems Presents Positive Phase II Data On Delcath PHP System In Treatment Of Inoperable Liver Metastases 28 March 2008
Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted In Higher SVR Than Flat Dosing; Low Relapse Rates In Patients With Chronic Hepatitis C 27 March 2008
Lifetime Effects Of Pediatric Liver Transplants 25 March 2008
BARACLUDE Data Show Low Resistance Over 5 Years In Nucleoside-Naive Hepatitis B Patients Baraclude(R) Data Continue To Demonstrate Low Incidence Of Resistance Through 5 Years Of Treatment IN NUCLeoside-naive Chronic Hepatitis B Patients Go To News Page: [1] 2 3 4 5 6 7 8 9 10 11 12 13 14 [Next] [Last Page] Contact Our News Editors For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to: (تم حذف الإيميل لأن عرضه مخالف لشروط المنتدى)[/color]"](تم حذف الإيميل لأن عرضه مخالف لشروط المنتدى)
Back to top Back to front page List of All Medical Articles Privacy Policy Terms and Conditions 2008 MediLexicon International Ltd
News Category Menu
- Liver Disease / Hepatitis
- >
Categories A-B
- Abortion
- Acid Reflux / GERD
- ADHD
- Aid / Disasters
- Alcohol / Addiction / Illegal Drugs
- Allergy
- Alternative Medicine
- Alzheimer's / Dementia
- Anxiety / Stress
- Arthritis
- Asthma
- Autism
- Bio-terrorism / Terrorism
- Biology / Biochemistry
- Bipolar
- Bird Flu / Avian Flu
- Blood / Hematology
- Body Aches
- Bones / Orthopaedics
- Breast Cancer
- >
Categories C-D
- Cancer / Oncology
- Cardiovascular / Cardiology
- Caregivers / Homecare
- Cervical Cancer / HPV Vaccine
- Cholesterol
- CJD / vCJD / Mad Cow Disease
- Cleft Palate
- Clinical Trials / Drug Trials
- Colorectal Cancer
- Complementary Medicine
- Compliance
- Conferences
- Cosmetic Medicine
- Crohn's
- Cystic Fibrosis
- Dentistry
- Depression
- Dermatology
- Diabetes
- Dyslexia
- >
Categories E-G
- Ear,
Nose and Throat
- Eating Disorders
- Endocrinology
- Epilepsy
- Erectile Dysfunction
- Eye Health / Blindness
- Fertility
- Flu / Cold / SARS
- GastroIntestinal / Gastroenterology
- Genetics
- Gout
- Gynecology
- >
Categories H-L
- Headache / Migraine
- Health Insurance / Medical Insurance
- Hearing / Deafness
- HIV / AIDS
- Huntingtons Disease
- Hypertension
- Immune System / Vaccines
- Infectious Diseases
- Irritable-Bowel Syndrome
- IT / Internet / E-mail
- Liver Disease / Hepatitis
- Lung Cancer
- Lupus
- Lymphoma / Leukemia
- >
Categories M-O
- Medical Devices
- Medical Malpractice / Litigation
- Medical Students / Training
- Medicare / Medicaid / SCHIP
- Men's health
- Mental Health
- MRI / PET / Ultrasound
- MRSA / Drug Resistance
- Multiple Sclerosis
- Muscular Dystrophy / ALS
- Neurology / Neuroscience
- Nursing / Midwifery
- Nutrition / Diet
- Obesity / Weight Loss / Fitness
- >
Categories P-R
- Pain
/ Anesthetics
- Parkinson's Disease
- Pediatrics / Children's Health
- Pharma / Biotech Industry
- Pharmacy / Pharmacists
- Plastic Surgery
- Pregnancy / Obstetrics
- Premature Ejaculation
- Primary Care / General Practice
- Prostate / Prostate Cancer
- Psychology / Psychiatry
- Public Health
- Radiology / Nuclear Medicine
- Regulatory Affairs / Drug Approvals
- Rehabilitation
- Respiratory
- >
Categories S-Z
- Schizophrenia
- Seniors / Aging
- Sexual Health / STDs
- Sleep / Sleep Disorders
- Smoking / Quit Smoking
- Sports Medicine / Fitness
- Statins
- Stem Cell Research
- Stroke / Neuroprotection
- Transplants / Organ Donations
- Tropical Diseases
- Urology / Nephrology
- Veterinary
- Viruses / Bacteria
- Water - Air Quality / Agriculture
- Women's Health
News By Email Weekly Newsletters Daily News Alerts Navigation Links Home About Us News Licensing Free Website Feeds Free Tools & ******* Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us Health Professional Sites Breast Cancer Cardiovascular GI Prostate Cancer Psychiatry Respiratory Learning Resources Migraine Urology Patient Resource Sites Asthma Bipolar Blood Pressure Breast Cancer (Patient) Heartburn Clinical Trials Today's Featured Health Videos
The Health Benefits of Coffee
Studies have shown that coffee may have health benefits in relation to many serious diseases, including cardiovascular disease, Type II diabetes, Parkinson's disease and also in cirrhosis and liver cancer. Experts believe this may be because coffee has high levels of antioxidants and magnesium. more videos are available in our health videos section.
Advertisements Baby Tooth Stem Cells We Store Lifesaving Stem Cells. BioEDEN has free info. Learn more now
Add Your Advertisement Here
Most Read Articles From The Last 7 Days Benefits In Chronic Pain Outweigh Risks For Painkiller Abuse 12 May 2008 Depressed Teenagers Making Themselves Worse With Marijuana Says US Government Report 12 May 2008 Evidence Discovered For Suspected Cause Of Type 1 Diabetes 12 May 2008 Mind: Return Of The Great Depression Causing Great Depression 12 May 2008 Pollution Linked To Deep Vein Thrombosis And Blood Clots 13 May 2008 Most Popular Categories public health neurology nutrition cancer cardiovascular hiv diabetes dermatology obesity alcohol psychology women's health infectious diseases pediatrics breast cancer urology pregnancy gastrointestinal pain respiratory prostate bones depression smoking medical devices health insurance medicare hypertension stem cell research biology alzheimer's sexual health sleep abortion genetics allergy autism eye health adhd it multiple sclerosis sports medicine pharma industry dentistry liver disease anxiety arthritis seniors cholesterol mrsa الموضوع : علاجات فى طور التنفيذ لفيروسات الكبد المصدر :منتديات تقى الإسلامية الكاتب: El Helalya |
| | | الجنه تنادينيالاشراف العام
تاريخ التسجيل : 16/05/2010
| | | | واسلاماهالمراقبة العامة
تاريخ التسجيل : 23/06/2009
| موضوع: رد: علاجات فى طور التنفيذ لفيروسات الكبد الجمعة 8 يوليو 2011 - 20:19 | |
| |
| | | | علاجات فى طور التنفيذ لفيروسات الكبد | |
|
مواضيع مماثلة | |
|
مواضيع مماثلة | |
| |
| |